{
  "chapter_title": "Business Activities",
  "section_title": "Operational Risk Factors",
  "description": "Pricing, forex exposure, commodities, sector cyclicality, high-risk sectors.",
  "questions": [
    {
      "question": "What are the key pricing risk factors for Ion Beam Applications SA, and how can they be mitigated?",
      "queries": [
        {
          "query": "Ion Beam Applications SA pricing risk factors",
          "results": [
            {
              "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "pricing exposure mitigation strategies for Ion Beam Applications SA",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "sector-specific pricing risks in the ion beam technology industry",
          "results": [
            {
              "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the operational risks associated with forex exposure for Ion Beam Applications SA, and how can they be managed?",
      "queries": [
        {
          "query": "Ion Beam Applications SA forex exposure risks",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "foreign exchange risk management strategies for the ion beam technology sector",
          "results": [
            {
              "text": "=== Page 59 ===\nIBA Annual Report 2023 \n56. IBA \ntransactions, with reporting to the Audit \nCommittee of the Group four times a year. The Group has certain investments In foreign \noperations, whose net assets are exposed to \nforeign currency translation risk. As appropriate, currency exposure arising from the net assets of \nthe Groups foreign operations may be managed \nthrough borrowings denominated in the relevant \ncurrencies. Proton Therapy segment is impacted by the \nfluctuation of the USD exchange rate against \nEUR.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "operational risks of currency fluctuations on company performance",
          "results": [
            {
              "text": "from net investments in non-Eurozone \noperations. Approximately 5.0% of the Groups \nsales (4.5% in 2022) are denominated in \ncurrencies other than the functional currency of \nthe operating unit making the sales, while 97.0% \nof costs (94.0% in 2022) are denominated in the \nunits functional currency. While the functional currency of the parent \ncompany of the Group is the euro, the Groups \nexposure to foreign currencies is related \nprimarily to the US dollar, Chinese yuan, Indian \nrupee, Russian ruble and Canadian dollar.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the major commodities involved in Ion Beam Applications SA's operations, and what are the associated operational risks?",
      "queries": [
        {
          "query": "Ion Beam Applications SA commodity exposure risk",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "commodity-related operational risks for the ion beam technology industry",
          "results": [
            {
              "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "sector-specific commodity price volatility risks",
          "results": [
            {
              "text": "luation method (fair \nvalue and carrying amount). The carrying \namount of these financial assets represents the \nmaximum credit exposure of the Group. Foreign currency risk \nThe Group operates internationally and as such, is exposed to foreign exchange risks arising from \ncommercial transactions (sales and supply \ncontracts), from financial assets and liabilities, and from net investments in non-Eurozone \noperations.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the key sector cyclicality risks for Ion Beam Applications SA, and how can they be addressed?",
      "queries": [
        {
          "query": "Ion Beam Applications SA sector cyclicality risks",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "cyclical risk management strategies for the ion beam technology sector",
          "results": [
            {
              "text": "assessing \nperformance of the operating segments. On the basis of its internal financial reports and given the Groups primary source \nof risk and profitability, IBA has identified two operating segments: - \nProton therapy and other accelerators: This segment constitutes the technological basis of the Groups many \nbusinesses and encompasses development, fabrication, and services associated with medical and industrial \nparticle accelerators and proton therapy systems. - \nDosimetry: This segment in",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "sector-specific economic downturn risks",
          "results": [
            {
              "text": "203-2 \nSignificant indirect economic impacts \np80 AR2023 Management report / corporate governance statement / codes of \nconduct / policy and targets \np7 AR2023 Patient care, what makes our heart beat \n205-3 \nConfirmed incidents of corruptions and \nactions taken \np51 AR2023 Management report / principal risks and uncertainties faced by the \ncompany \nGRI 2016 \np45 AR2023 Management report / highlights of the year",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    }
  ]
}